LALPATHLAB - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.4
| Stock Code | LALPATHLAB | Market Cap | 23,430 Cr. | Current Price | 1,398 ₹ | High / Low | 1,771 ₹ |
| Stock P/E | 43.7 | Book Value | 140 ₹ | Dividend Yield | 0.86 % | ROCE | 30.6 % |
| ROE | 24.7 % | Face Value | 10.0 ₹ | DMA 50 | 1,447 ₹ | DMA 200 | 1,486 ₹ |
| Chg in FII Hold | -1.57 % | Chg in DII Hold | 0.98 % | PAT Qtr | 113 Cr. | PAT Prev Qtr | 146 Cr. |
| RSI | 46.6 | MACD | -11.2 | Volume | 3,30,910 | Avg Vol 1Wk | 2,82,913 |
| Low price | 1,147 ₹ | High price | 1,771 ₹ | PEG Ratio | 3.31 | Debt to equity | 0.06 |
| 52w Index | 40.2 % | Qtr Profit Var | 7.24 % | EPS | 30.8 ₹ | Industry PE | 35.7 |
📊 Analysis: LALPATHLAB is trading at 1,398 ₹, below both its 50 DMA (1,447 ₹) and 200 DMA (1,486 ₹), showing weak technical strength. RSI at 46.6 indicates neutral-to-weak momentum, while MACD (-11.2) suggests bearish undertone. Current volume (3.30L) is slightly above the 1-week average (2.82L), pointing to steady intraday participation. The setup favors cautious trades with limited upside potential.
💰 Optimal Buy Price: 1,390–1,405 ₹ (near support zone)
📈 Profit-Taking Levels: 1,420–1,440 ₹ (short-term resistance)
⚠️ Stop-Loss: 1,375 ₹ (below support)
⏳ If Already Holding: Exit intraday if price fails to sustain above 1,390 ₹ or if RSI dips below 45 with weakening momentum. Book profits near 1,420–1,440 ₹ if momentum slows. Watch MACD widening negatively as a clear exit signal.
Positive
- Strong ROCE (30.6%) and ROE (24.7%) indicate efficient capital use.
- Debt-to-equity ratio of 0.06 shows low leverage.
- DII holdings increased (+0.98%), reflecting domestic institutional support.
- Quarterly PAT of 113 Cr. remains healthy despite decline.
- Dividend yield of 0.86% adds investor confidence.
Limitation
- Trading below both 50 DMA and 200 DMA, showing weak technicals.
- High P/E (43.7) compared to industry average (35.7), suggesting overvaluation.
- MACD negative, indicating weak short-term momentum.
- PEG ratio (3.31) signals expensive valuation relative to growth.
- Quarterly PAT declined from 146 Cr. to 113 Cr.
Company Negative News
- No major external negative news reported, but FII outflow (-1.57%) and earnings decline are concerns.
Company Positive News
- Quarterly PAT remains positive, showing resilience despite decline.
- DII holdings increased, reflecting confidence from domestic institutions.
Industry
- Industry P/E at 35.7 is lower than LALPATHLAB’s P/E (43.7), highlighting relative overvaluation.
- Diagnostics and healthcare sector remains resilient with steady demand, though valuations are stretched.
Conclusion
🔎 LALPATHLAB offers moderate intraday potential with support near 1,390 ₹ and resistance around 1,420–1,440 ₹. Momentum indicators suggest caution, as MACD is negative and RSI is weak. Best strategy: Buy near support, exit near resistance, and protect downside with a strict stop-loss at 1,375 ₹.